Last reviewed · How we verify
RJK-RT2831 dose-escalation phase Ia — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
RJK-RT2831 dose-escalation phase Ia (RJK-RT2831 dose-escalation phase Ia) — Nanjing RegeneCore Biotech Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| RJK-RT2831 dose-escalation phase Ia TARGET | RJK-RT2831 dose-escalation phase Ia | Nanjing RegeneCore Biotech Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- RJK-RT2831 dose-escalation phase Ia CI watch — RSS
- RJK-RT2831 dose-escalation phase Ia CI watch — Atom
- RJK-RT2831 dose-escalation phase Ia CI watch — JSON
- RJK-RT2831 dose-escalation phase Ia alone — RSS
Cite this brief
Drug Landscape (2026). RJK-RT2831 dose-escalation phase Ia — Competitive Intelligence Brief. https://druglandscape.com/ci/rjk-rt2831-dose-escalation-phase-ia. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab